ReviewJournal of renal injury prevention2013
Diabetic kidney disease; review of the current knowledge.
Review in Journal of renal injury prevention, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 2 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Determinants of diabetic nephropathy among diabetic patients in Ethiopia: Systematic review and meta-analysis.PloS one · 2024Pooled it
- Flash Glucose Monitoring System for People with Type 1 or Type 2 Diabetes: A Health Technology Assessment.Ontario health technology assessment series · 2019Pooled it
- Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study.Diabetes technology & therapeutics · 2018 · on this mapTrial
- Psoriasis risk in patients with diabetic retinopathy: A nationwide population-based study.Scientific reports · 2018Trial
- The roles of free-fatty acid receptors in the pathophysiology of renal disorders.The Journal of pharmacology and experimental therapeutics · 2026Review
- Investigation and future trend prediction of disease burden of chronic kidney disease due to diabetes mellitus type 2 globally and in China from 1990 to 2021.Journal of diabetes investigation · 2026Article
- A dataset of demographic and lifestyle risk factors for assessing chronic kidney disease development in diabetic patients.Data in brief · 2026Article
- Cepharanthine improves blood glucose levels and mitigates renal injury in streptozotocin-induced diabetic rats via restoring pancreatic β-cell integrity and reducing inflammation.Frontiers in pharmacology · 2026Article
- Role for plant foods in kidney health among middle-aged individuals environmentally exposed to cadmium and lead.PloS one · 2026Article
- Glomerular ultrastructural change and vascular endothelial growth factor-A expression in diabetic cats.The Journal of small animal practice · 2025Article
- Study of MicroRNA-192 as an Early Biomarker for Diagnosis of Diabetic Nephropathy.Diagnostics (Basel, Switzerland) · 2025Article
- Proanthocyanidin offers protection against diabetic nephropathy: elucidation of its mechanism of action using animal models.Pharmaceutical biology · 2024Review
- Identification of functional heterogeneity of immune cells and tubular-immune cellular interplay action in diabetic kidney disease.Journal of translational internal medicine · 2024Article
- Exploring potential risk factors for lower limb amputation in people with diabetes-A national observational cohort study in Sweden.Journal of foot and ankle research · 2024Observational
- Perioperative Management of Patients with Diabetes and Cancer: Challenges and Opportunities.Cancers · 2024Review
- Knowledge of Diabetes Mellitus and Practices Regarding Lifestyle Factors and Diabetes Management in a General Adult Population of Aseer Region, Saudi Arabia.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Comparative Determination of Glomerular Filtration Rate Estimation Formulae in Type 2 Diabetic Patients: An Observational Study.BioMed research international · 2024Observational
- Diabetes Pay-for-Performance Program Participation and Dialysis Risk in Relation to Educational Attainment: A Retrospective Cohort Study.Healthcare (Basel, Switzerland) · 2023Article
- Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome.Frontiers in endocrinology · 2023Review
- Role of neutrophil-lymphocyte ratio as a prognostic marker for type 2 diabetic nephropathy among Indians.Bioinformation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) in most parts of the world. 20 to 30% of diabetic patient have diabetic nephropathy in type 1 and type 2. Hyperglycemia is the key of nephropathy creation. Hyperglycemia also by production of toxic materials, advanced glycosylated end product (AGE), increased activity of aldose reductase has some role. Some metabolites of arachidonic acid, hemodynamic derangements and genetic factors have also some role. Although diabetic nephropathy is most common cause of nephropathy in these patients, but diabetic patients are also prone to other urinary tract and renal parenchymal disease and should not be confused with renal failure due to diabetic nephropathy. The principle of treatment of diabetic nephropathy is based on tight control of hyperglycemia, tight control of blood pressure and glomerular pressure, control of dyslipidemia, restriction of protein intake and smoking withdrawal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.